Immunoproteomic Profiling of Bordetella pertussis Outer Membrane Vesicle Vaccine Reveals Broad and Balanced Humoral Immunogenicity.

The current resurgence of whooping cough is alarming, and improved pertussis vaccines are thought to offer a solution. Outer membrane vesicle vaccines (omvPV) are potential vaccine candidates, but omvPV-induced humoral responses have not yet been characterized in detail. The purpose of this study was to determine the antigen composition of omvPV and to elucidate the immunogenicity of the individual antigens. Quantitative proteome analysis revealed the complex composition of omvPV. The omvPV immunogenicity profile in mice was compared to those of classic whole cell vaccine (wPV), acellular vaccine (aPV), and pertussis infection. Pertussis-specific antibody levels, antibody isotypes, IgG subclasses, and antigen specificity were determined after vaccination or infection by using a combination of multiplex immunoassays, two-dimensional immunoblotting, and mass spectrometry. The vaccines and infection raised strong antibody responses, but large quantitative and qualitative differences were measured. The highest antibody levels were obtained by omvPV. All IgG subclasses (IgG1/IgG2a/IgG2b/IgG3) were elicited by omvPV and in a lower magnitude by wPV, but not by aPV (IgG1) or infection (IgG2a/b). The majority of omvPV-induced antibodies were directed against Vag8, BrkA, and LPS. The broad and balanced humoral response makes omvPV a promising pertussis vaccine candidate.

[1]  C. Boog,et al.  Modulation of the CD4(+) T cell response after acellular pertussis vaccination in the presence of TLR4 ligation. , 2015, Vaccine.

[2]  M. Rumbo,et al.  Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles. , 2014, Vaccine.

[3]  J. Geurtsen,et al.  Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis , 2014, Expert review of vaccines.

[4]  J. Pennings,et al.  Molecular Signatures of the Evolving Immune Response in Mice following a Bordetella pertussis Infection , 2014, PloS one.

[5]  Aldert L. Zomer,et al.  Proteomics-Identified Bvg-Activated Autotransporters Protect against Bordetella pertussis in a Mouse Model , 2014, PloS one.

[6]  P. A. van der Ley,et al.  Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. , 2014, Vaccine.

[7]  T. Merkel,et al.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model , 2013, Proceedings of the National Academy of Sciences.

[8]  A. Rowhani-Rahbar,et al.  Effectiveness of pertussis vaccines for adolescents and adults: case-control study , 2013, BMJ.

[9]  K. Mills,et al.  Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine , 2013, PLoS pathogens.

[10]  J. Pennings,et al.  Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines. , 2013, Journal of proteome research.

[11]  Harm HogenEsch,et al.  Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants , 2013, Front. Immun..

[12]  T. Merkel,et al.  Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates , 2012, Mucosal Immunology.

[13]  T. Clark,et al.  Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. , 2012, JAMA.

[14]  J. Cherry.  Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease. , 2012, The New England journal of medicine.

[15]  P. Bruhns.  Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.

[16]  M. Hecker,et al.  A comprehensive analysis of Bordetella pertussis surface proteome and identification of new immunogenic proteins. , 2011, Vaccine.

[17]  D. Maskell,et al.  Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine , 2011, Proceedings of the National Academy of Sciences.

[18]  C. Boog,et al.  Fast, Antigen-Saving Multiplex Immunoassay To Determine Levels and Avidity of Mouse Serum Antibodies to Pertussis, Diphtheria, and Tetanus Antigens , 2011, Clinical and Vaccine Immunology.

[19]  L. Babiuk,et al.  Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. , 2011, Vaccine.

[20]  F. Mooi,et al.  Comparative genomics of prevaccination and modern Bordetella pertussis strains , 2010, BMC Genomics.

[21]  Chengping Lu,et al.  Immunoproteomic Analysis of Human Serological Antibody Responses to Vaccination with Whole-Cell Pertussis Vaccine (WCV) , 2010, PloS one.

[22]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[23]  Thomas Korn,et al.  Proinflammatory T helper type 17 cells are effective B-cell helpers , 2010, Proceedings of the National Academy of Sciences.

[24]  Ping Chen,et al.  Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. , 2010, Vaccine.

[25]  M. Kretzschmar,et al.  Incidence and Reproduction Numbers of Pertussis: Estimates from Serological and Social Contact Data in Five European Countries , 2010, PLoS medicine.

[26]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[27]  I. Bekeredjian-Ding,et al.  Toll‐like receptors – sentries in the B‐cell response , 2009, Immunology.

[28]  M. Hecker,et al.  Immunoproteomic analysis of Bordetella pertussis and identification of new immunogenic proteins. , 2009, Vaccine.

[29]  N. Carbonetti,et al.  Role of Neutrophils in Response to Bordetella pertussis Infection in Mice , 2008, Infection and Immunity.

[30]  I. Cohen,et al.  Induction of IgG3 to LPS via Toll-Like Receptor 4 Co-Stimulation , 2008, PloS one.

[31]  M. Rumbo,et al.  Outer membrane vesicles as acellular vaccine against pertussis. , 2008, Vaccine.

[32]  R. Fernandez,et al.  Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. , 2008, Vaccine.

[33]  N. Binsztein,et al.  Pulsed-Field Gel Electrophoresis, Pertactin, Pertussis Toxin S1 Subunit Polymorphisms, and Surfaceome Analysis of Vaccine and Clinical Bordetella pertussis Strains , 2007, Clinical and Vaccine Immunology.

[34]  C. Locht,et al.  Live Attenuated B. pertussis as a Single-Dose Nasal Vaccine against Whooping Cough , 2006, PLoS pathogens.

[35]  M. Gorenstein,et al.  Absolute Quantification of Proteins by LCMSE , 2006, Molecular & Cellular Proteomics.

[36]  O. Bjørnstad,et al.  Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. , 2005, The Journal of clinical investigation.

[37]  M. Kuehn,et al.  Bacterial outer membrane vesicles and the host-pathogen interaction. , 2005, Genes & development.

[38]  M. Massari,et al.  Resurgence of Pertussis in Europe , 2005, The Pediatric infectious disease journal.

[39]  P. Bruhns,et al.  FcγRIV : A novel FcR with distinct IgG subclass specificity , 2005 .

[40]  F. Mooi,et al.  The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. , 2005, Protein expression and purification.

[41]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[42]  T. Michaelsen,et al.  The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis , 2004, Scandinavian journal of immunology.

[43]  F. Mooi,et al.  Crucial role of antibodies to pertactin in Bordetella pertussis immunity. , 2003, The Journal of infectious diseases.

[44]  H. Meiring,et al.  Nanoscale LC–MS(n): technical design and applications to peptide and protein analysis , 2002 .

[45]  M. E. Rodriguez,et al.  Fc Receptor-Mediated Immunity Against Bordetella pertussis1 , 2001, The Journal of Immunology.

[46]  R. Fernandez,et al.  Antibodies to BrkA augment killing of Bordetella pertussis. , 2001, Vaccine.

[47]  F. Mooi,et al.  Targeting to Fcgamma receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis. , 2001, The Journal of infectious diseases.

[48]  F. Mooi,et al.  Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens. , 2000, Vaccine.

[49]  M. Corbel,et al.  Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines. , 2000, Vaccine.

[50]  R. Wait,et al.  A modified silver staining protocol for visualization of proteins compatible with matrix‐assisted laser desorption/ionization and electrospray ionization‐ mass spectrometry , 2000, Electrophoresis.

[51]  J. Brisson,et al.  Structure of the Bordetella pertussis 1414 endotoxin , 2000, FEBS letters.

[52]  P. Sly,et al.  Antigen-Specific Responses to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Human Infants Are Initially Th2 Polarized , 2000, Infection and Immunity.

[53]  R. Schneerson,et al.  Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. , 2000, The Journal of infectious diseases.

[54]  R. Fernandez,et al.  Characterization of Human Bactericidal Antibodies to Bordetella pertussis , 1999, Infection and Immunity.

[55]  H. Hallander,et al.  Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. , 1998, Vaccine.

[56]  T. K. van den Berg,et al.  Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). , 1998, Journal of immunology.

[57]  T. Finn,et al.  Vag8, a Bordetella pertussis bvg-Regulated Protein , 1998, Infection and Immunity.

[58]  R. Rappuoli,et al.  A Recombinant Live Attenuated Strain of Vibrio cholerae Induces Immunity against Tetanus Toxin andBordetella pertussis Tracheal Colonization Factor , 1998, Infection and Immunity.

[59]  K. Mills,et al.  A Murine Model in Which Protection Correlates with Pertussis Vaccine Efficacy in Children Reveals Complementary Roles for Humoral and Cell-Mediated Immunity in Protection againstBordetella pertussis , 1998, Infection and Immunity.

[60]  T. Finn,et al.  Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant , 1995, Molecular microbiology.

[61]  F. Podlaski,et al.  Interleukin‐12 profoundly up‐regulates the synthesis of antigen‐specific complement‐fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo , 1995, European journal of immunology.

[62]  K. Mills,et al.  Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity , 1993, Infection and immunity.

[63]  A. Kimura,et al.  A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis , 1992, Infection and immunity.

[64]  D. Welch,et al.  Applications of cellular fatty acid analysis , 1991, Clinical Microbiology Reviews.

[65]  M. Kessel,et al.  Purification and immunological characterization of a GroEL-like protein from Bordetella pertussis , 1991, Infection and immunity.

[66]  R. Fernandez-Botran,et al.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells , 1988, Nature.

[67]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[68]  P. Bruhns,et al.  FcgammaRIV: a novel FcR with distinct IgG subclass specificity. , 2005, Immunity.

[69]  J. Poolman,et al.  The purification and protective capacity of Bordetella pertussis outer membrane proteins. , 1995, Vaccine.